Details werden geladen...
Traws Pharma Provides Regulatory Update on Influenza Program | The Manila Times
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).
Ähnliche Seiten
MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease
https://www.finanznachrichten.de/nachrichten-2026-05/68553354-maat-pharma-provides-an-update-on-the-application-for-marketing-authorization-of-maat013-xervyteg-in-the-treatment-of-acute-graft-versus-host-diseas-004.htm
Tinkerine Studios Ltd. Provides Update on Regulatory and Corporate Conditions for Proposed Reverse Takeover with Fotonara Inc. | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/tinkerine-studios-ltd-provides-update-on-regulatory-and-corporate-conditions-for-proposed-reverse-takeover-with-fotonara-inc/2356994Diginex Provides Update on Proposed Resulticks Acquisition | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/diginex-provides-update-on-proposed-resulticks-acquisition/2357776Critical Metals Corp. Provides Project Update on Acceleration Plan and Tanbreez Development Progress | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/critical-metals-corp-provides-project-update-on-acceleration-plan-and-tanbreez-development-progress/2357019Structure Therapeutics Announces Participation in Upcoming Investor Conferences | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/structure-therapeutics-announces-participation-in-upcoming-investor-conferences/2352124